In 2025, Japanese companies executed 24 cross‑border M&A transactions in the healthcare sector across the Asia–Pacific region. Activity was widely distributed across pharmaceutical manufacturing and distribution, consumer healthcare, digital health, and adjacent medical‑service platforms. A consistent pattern emerged: Japanese corporates expanded commercial networks in high‑growth ASEAN markets such as Vietnam and the Philippines, while deploying…